These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 21493064

  • 1. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.
    Wang L, Hubert JA, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, MacNeil DJ, Weber AE, Edmondson SD.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2911-5. PubMed ID: 21493064
    [Abstract] [Full Text] [Related]

  • 2. Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists.
    Cameron KO, Beretta EE, Chen Y, Chu-Moyer M, Fernando D, Gao H, Kohrt J, Lavergne S, Jardine Pda S, Guzman-Perez A, Hoth C, Perry DA, Hadcock JR, Gautreau D, Makowski M, Perez S, Polivkova J, Rogers L, Scott DO, Swick AG, Thiede L, Trebino CE, Trilles RV, Wilmowski J, Zhang Y.
    Bioorg Med Chem Lett; 2012 Apr 15; 22(8):2943-7. PubMed ID: 22424974
    [Abstract] [Full Text] [Related]

  • 3. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
    Zhu C, Hansen AR, Bateman T, Chen Z, Holt TG, Hubert JA, Karanam BV, Lee SJ, Pan J, Qian S, Reddy VB, Reitman ML, Strack AM, Tong V, Weingarth DT, Wolff MS, MacNeil DJ, Weber AE, Duffy JL, Edmondson SD.
    Bioorg Med Chem Lett; 2008 Aug 01; 18(15):4393-6. PubMed ID: 18614364
    [Abstract] [Full Text] [Related]

  • 4. 2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.
    Berger R, Zhu C, Hansen AR, Harper B, Chen Z, Holt TG, Hubert J, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, Wolff M, Macneil DJ, Weber AE, Edmondson SD.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4833-7. PubMed ID: 18684621
    [Abstract] [Full Text] [Related]

  • 5. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL, Newcomb JR, Nunes JJ, Boucher C, Cheng AC, DiMauro EF, Epstein LF, Gallant P, Hodous BL, Huang X, Lee JH, Patel VF, Schneider S, Turci SM, Zhu X.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1172-6. PubMed ID: 18083554
    [Abstract] [Full Text] [Related]

  • 6. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
    Wilson KJ, Illig CR, Chen J, Wall MJ, Ballentine SK, DesJarlais RL, Chen Y, Schubert C, Donatelli R, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3925-9. PubMed ID: 20570147
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
    Lattmann E, Singh H, Boonprakob Y, Lattmann P, Sattayasai J.
    J Pharm Pharmacol; 2006 Mar 01; 58(3):393-401. PubMed ID: 16536908
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
    Ramurthy S, Aikawa M, Amiri P, Costales A, Hashash A, Jansen JM, Lin S, Ma S, Renhowe PA, Shafer CM, Subramanian S, Sung L, Verhagen J.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3286-9. PubMed ID: 21543226
    [Abstract] [Full Text] [Related]

  • 9. Novel heterocyclic family of phenyl naphthothiazole carboxamides derived from naphthalimides: synthesis, antitumor evaluation, and DNA photocleavage.
    Li Z, Yang Q, Qian X.
    Bioorg Med Chem; 2005 May 02; 13(9):3149-55. PubMed ID: 15809150
    [Abstract] [Full Text] [Related]

  • 10. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.
    Wu Z, Yang C, Graham TH, Verras A, Chabin RM, Xu S, Tong X, Xie D, Lassman ME, Bhatt UR, Garcia-Calvo MM, Shen Z, Chen Q, Bleasby K, Sinharoy R, Hale JJ, Tata JR, Pinto S, Colletti SL, Shen DM.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1727-30. PubMed ID: 22290078
    [Abstract] [Full Text] [Related]

  • 11. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
    Ramurthy S, Costales A, Jansen JM, Levine B, Renhowe PA, Shafer CM, Subramanian S.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1678-81. PubMed ID: 22264479
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M, Bartolomé-Nebreda JM, Gómez-Monterrey I, González-Muñiz R, García-López MT, Ballaz S, Barber A, Fortuño A, Del Río J, Herranz R.
    J Med Chem; 1997 Oct 10; 40(21):3402-7. PubMed ID: 9341915
    [Abstract] [Full Text] [Related]

  • 13. Research on heterocyclic compounds. XXXVIII. Synthesis and pharmacological activity of imidazo[1,2-b]pyridazine-2-carboxylic derivatives.
    Luraschi E, Arena F, Sacchi A, Laneri S, Abignente E, Avallone L, D'Amico M, Berrino L, Rossi F.
    Farmaco; 1997 Apr 10; 52(4):213-7. PubMed ID: 9241825
    [Abstract] [Full Text] [Related]

  • 14. Structure-activity relationships of adenosines with heterocyclic N6-substituents.
    Ashton TD, Aumann KM, Baker SP, Schiesser CH, Scammells PJ.
    Bioorg Med Chem Lett; 2007 Dec 15; 17(24):6779-84. PubMed ID: 17967536
    [Abstract] [Full Text] [Related]

  • 15. Discovery and Synthesis of Heterocyclic Carboxamide Derivatives as Potent Anti-norovirus Agents.
    Ohba M, Oka T, Ando T, Arahata S, Ikegaya A, Takagi H, Ogo N, Owada K, Kawamori F, Wang Q, Saif LJ, Asai A.
    Chem Pharm Bull (Tokyo); 2016 Dec 15; 64(5):465-75. PubMed ID: 27150478
    [Abstract] [Full Text] [Related]

  • 16. Pyrazolo[1,5-a]pyrimidines as estrogen receptor ligands: defining the orientation of a novel heterocyclic core.
    Compton DR, Carlson KE, Katzenellenbogen JA.
    Bioorg Med Chem Lett; 2004 Nov 15; 14(22):5681-4. PubMed ID: 15482947
    [Abstract] [Full Text] [Related]

  • 17. Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists.
    Blanc-Delmas E, Lebegue N, Wallez V, Leclerc V, Yous S, Carato P, Farce A, Bennejean C, Renard P, Caignard DH, Audinot-Bouchez V, Chomarat P, Boutin J, Hennuyer N, Louche K, Carmona MC, Staels B, Pénicaud L, Casteilla L, Lonchampt M, Dacquet C, Chavatte P, Berthelot P, Lesieur D.
    Bioorg Med Chem; 2006 Nov 15; 14(22):7377-91. PubMed ID: 16887353
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.
    Kiyoi T, York M, Francis S, Edwards D, Walker G, Houghton AK, Cottney JE, Baker J, Adam JM.
    Bioorg Med Chem Lett; 2010 Aug 15; 20(16):4918-21. PubMed ID: 20634067
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists.
    Xin Z, Zhao H, Serby MD, Liu B, Schaefer VG, Falls DH, Kaszubska W, Colins CA, Sham HL, Liu G.
    Bioorg Med Chem Lett; 2005 Feb 15; 15(4):1201-4. PubMed ID: 15686942
    [Abstract] [Full Text] [Related]

  • 20. The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
    Napier S, Wishart G, Arbuckle W, Baker J, Barn D, Bingham M, Brown A, Byford A, Claxton C, Craighead M, Buchanan K, Fielding L, Gibson L, Goodwin R, Goutcher S, Irving N, MacSweeney C, Milne R, Mort C, Presland J, Sloan H, Thomson F, Turnbull Z, Young T.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):3163-7. PubMed ID: 21458261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.